ClinicalTrials.gg
CompletedNCT05784597FAPrimoUpdated Nov 15, 2024

A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors

A Phase 1 interventional study of [68Ga]Ga-OncoFAP administration in Breast Cancer, Colorectal Cancer and Oesophageal Cancer, sponsored by Philogen S.p.A.. Completed at 5 sites in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-15.

Sponsored by Philogen S.p.A. · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 886 studies in Breast Neoplasms with a site in Italy — 230 open to participants now, 350 under way, 86 of them phase 3. Breast Neoplasms · Italy.

Enrollment
658th of 686
18 · median 209
Started
2023
with 75 others
Phase 1
48 of 886
6 open now
Registered
607th of 886
by date

Among the 886 studies in Breast Neoplasms with a site in Italy, this one is the 658th largest by enrollment of the 686 interventional ones that give a count, is one of 76 that started in 2023, is one of 48 in phase 1, and was the 607th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

230 of the 886 studies in Breast Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

225 more — sign in →

All 230 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 886 studies in Breast Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

The primary objectives of this trial are to evaluate the safety and dosimetry of [68Ga]Ga-OncoFAP for detection/imaging of solid tumors.

Read the detailed description

Phase I, multicenter study in patients with a confirmed diagnosis of solid tumor among breast cancer, colorectal cancer, oesophageal cancer and pancreatic adenocarcinoma, requiring clinical staging for nodal staging and/or metastatic disease (based on institutional practice and risk stratification). All patients will receive a single intravenous bolus administration of 250 MBq (225 - 275 MBq). [68Ga]Ga-OncoFAP biodistribution, PK, and dosimetry of [68Ga]Ga-OncoFAP will be assessed based on a series of PET/CT scans, blood and urine sampling.

03

Conditions studied

  • Breast Cancer
  • Colorectal Cancer
  • Oesophageal Cancer
  • Pancreas Adenocarcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with a confirmed diagnosis of breast cancer, colorectal cancer, oesophageal cancer and pancreatic adenocarcinoma. Confirmation by histopathology is required for breast, colorectal and oesophageal cancer. For pancreatic adenocarcinoma, confirmation by histopathology or cytology obtained by endoscopic ultrasound is accepted.
  2. Requirement for diagnostic imaging or imaging performed within 4 weeks prior to the [68Ga]Ga-OncoFAP-PET/CT scan for staging.
  3. Male or non-pregnant and non-breastfeeding female.
  4. For female patients: negative serum pregnancy test for women of * (WOCBP).

    WOCBP must agree to use, from the screening to six months following the study drug administration, highly effective methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu/ctfg.html) and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion or vasectomized partner.

  5. For male patients: male subject able to father children must agree to practice effective contraception for three months starting from the study drug administration.
  6. Age 18 - 75
  7. ≤ 1
  8. Patient must not have any concomitant infections or active concomitant disease.
  9. of more than 12 weeks.
  10. Ability to undergo imaging study procedures.
  11. Evidence of a personally signed and dated document indicating that the subject has been informed of all pertinent aspects of the study.
  12. Willingness and ability to comply with the scheduled visits, plan, laboratory tests and other study procedures.

    • Women of childbearing potential are defined as females who have experienced menarche, are not (12 months with no menses without an alternative medical cause) and are not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy).

Exclusion criteria

Exclusion Criteria:

  1. Chronically impaired renal function as expressed by \< 60 mL/min or serum creatinine > 1.5 x .
  2. Presence of active hepatitis.
  3. Presence of significant cardiac disorders (congestive heart failure, class III-IV, myocardial infarction within one year prior to study entry, uncontrolled hypertension, or arrhythmia).
  4. Pregnant or breastfeeding during participation in the study.
  5. Any concomitant condition which in the opinion of investigators makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol.
  6. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery) within 4 weeks of administration of the study drug. Minimally invasive procedures such as are not considered as exclusion criteria.
  7. Serious, non-healing wound, ulcer, or bone fracture.
  8. Allergy to study medication or in study medication.
  9. Any anti-cancer therapy (e.g. cytotoxic chemotherapy, immunotherapy, radiation, surgery, etc.) within 3 weeks before [68Ga]Ga-OncoFAP-PET/CT scan
  10. Subject has received, or is scheduled to receive, another medicinal product (IMP) from 1 month before [68Ga]Ga-OncoFAP injection to end of study participation.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Cohort A

    3 female + 3 male patients with a primary tumor only

    Drug: [68Ga]Ga-OncoFAP administration

  • Experimental
    Cohort B

    Patients with a primary tumor and/or advanced/metastatic disease with a quantifiable number of lesions

    Drug: [68Ga]Ga-OncoFAP administration

Interventions

06

What researchers measure

Primary outcomes

  1. Safety (AE)

    Safety of administration of 68Ga-OncoFAP, assessed based on Common Toxicity Criteria (CTCAE version 5.0)

    Time frame: Throughout study, until a maximum of 8 days after the completion of each patient

  2. Cohort A: Dosimetry - Effective dose equivalent (mSv)

    Effective dose equivalent (mSv) of normal organs following administration of a single dose of \[68Ga\]Ga-OncoFAP, for patients in cohort A

    Time frame: Assessed on day 1

  3. Cohort A: Dosimetry - Absorbed doses (mGy)

    Absorbed doses (mGy) of normal organs following administration of a single dose of \[68Ga\]Ga-OncoFAP, for patients in cohort A

    Time frame: Assessed on day 1

Secondary outcomes

  1. Biodistribution profile: SUVmax

    Uptake of \[68Ga\]Ga-OncoFAP in terms of SUVmax

    Time frame: Assessed on day 1

  2. Biodistribution profile: SUVmean

    Uptake of \[68Ga\]Ga-OncoFAP in terms of SUVmean

    Time frame: Assessed on day 1

  3. Biodistribution profile: SUVsd

    Uptake of \[68Ga\]Ga-OncoFAP in terms of SUVsd

    Time frame: Assessed on day 1

  4. PK

    Pharmacokinetics of \[68Ga\]Ga-OncoFAP based on measurement of residual radioactivity in the blood over time \[MBq/mL

    Time frame: Assessed on day 1

  5. Excretion

    Metabolism and excretion of \[68Ga\]Ga-OncoFAP based on radioactivity measurements on urine collected at defined timepoints

    Time frame: Assessed on day 1

  6. Immunopathology staining

    Correlation of \[68Ga\]Ga-OncoFAP uptake with immunopathology staining if and when surgical or biopsy specimen are available

    Time frame: Assessed on day 1

  7. Lesion detection rate

    Lesion detection rate compared to standard imaging

    Time frame: Assessed on day 1

07

Study locations

5 sites
  • Istituto Clinico Humanitas
    Rozzano, Milano 20089, Italy
  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
    Meldola, 47014, Italy
  • IRCCS San Raffaele
    Milano, 20132, Italy
  • Istituto Nazionale dei Tumori | Fondazione IRCCS
    Milano, 20133, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, 56126, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Oct 2024, 17 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 17 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2022
First posted
Mar 27, 2023
StartActual
Apr 27, 2023
Primary completionActual
Oct 21, 2024
CompletionActual
Oct 21, 2024
Last update
Nov 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05784597
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
Mar 27, 2023
Start date
Apr 27, 2023
Primary completion
Oct 21, 2024
Completion
Oct 21, 2024
Last update
Nov 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium-68

Start the discussion